CSIMarket
 
Flexion Therapeutics Inc   (FLXN)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 50
 Employees 215
 Revenues (TTM) (Millions $) 100
 Net Income (TTM) (Millions $) -101
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 3

Flexion Therapeutics Inc
Flexion Therapeutics Inc is a clinical stage biopharmaceutical company headquartered in Burlington, Massachusetts. It was founded in 2007 by Dr. Michael Clayman, an accomplished pharmaceutical executive, with a mission to develop differentiated, localized therapies for patients with musculoskeletal conditions. The company has a single focus on developing novel and innovative therapies for patients with osteoarthritis (OA), a degenerative joint disease that affects millions of people worldwide.

Flexion's lead product candidate is Zilretta, a sustained-release, intra-articular steroid injection for the treatment of OA-related knee pain. Zilretta's proprietary formulation of triamcinolone acetonide (TCA) is designed to provide prolonged pain relief for up to three months with a single injection. Flexion obtained FDA approval for Zilretta in October 2017, making it the first and only intra-articular extended-release steroid indicated for knee OA in the US.

Flexion is also developing FX201, a locally administered gene therapy candidate for the treatment of OA. FX201 is designed to inhibit the inflammatory cascade responsible for cartilage degradation by delivering a highly-specific RNA interference (RNAi) molecule to the affected joint. Clinical data from early-stage studies suggest that FX201 has the potential to be a highly-effective and safe treatment for OA.

In addition to its primary focus on OA, Flexion is also exploring opportunities to expand its pipeline into other musculoskeletal disorders, including back pain, joint pain, and tendinopathies. The company's advanced research capabilities and strong scientific expertise position it as a key player in the rapidly growing musculoskeletal market.

Flexion's management team is led by Dr. Michael Clayman, the company's founder and CEO, who brings extensive experience in the life sciences industry. The company's board of directors and scientific advisory board includes experts in the fields of medicine, biotechnology, and drug development, providing valuable guidance and support to the company's research efforts.

In summary, Flexion Therapeutics Inc is a biopharmaceutical company with a single focus on developing innovative therapies for patients with musculoskeletal disorders. Its lead product candidate, Zilretta, is the first and only intra-articular extended-release steroid approved by the FDA for the treatment of knee OA. The company's pipeline includes promising candidates such as FX201, a locally administered gene therapy for OA. Flexion's strong research capabilities, management team, and scientific advisory board make it a key player in the musculoskeletal market.


   Company Address: 10 Mall Road Burlington 1803 MA
   Company Phone Number: 305-7777   Stock Exchange / Ticker: NASDAQ FLXN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

Flexion Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com